HFSR is a common side effect of tyrosine kinase inhibitors. Credit: Scotto Bear / Flickr (Creative Commons).

Targeted oncology supportive therapy company OnQuality Pharmaceuticals has enrolled the first participant in Part 2 of the NOVA-II Phase II clinical trial of OQL011 to manage Hand-Foot Skin Reaction (HFSR) in cancer patients.

The topical ointment will be evaluated in the patients who are receiving vascular endothelial growth factor receptor inhibitor(s) (VEGFRi) as part of their treatment.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The international multicentre, double-blinded, randomised, vehicle-controlled, dose-ranging trial will evaluate OQL011’s safety and efficacy as a topical ointment to treat VEGFR inhibitor-associated HFSR.

Those eligible for the trial must receive VEGFR inhibitor-based anticancer therapy and have HFSR severity of grade 3 or higher.

Preliminary data from the trial’s first part showed OQL011 to be safe and well tolerated without any significant adverse events.

See Also:

OnQuality Pharmaceuticals chief medical officer and co-founder Hong Tang said: “Our team is delighted to start Part 2 of the NOVA-II clinical trial to address the unmet need for cancer-therapy-induced skin toxicities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“OQL011 generated positive initial findings in Part 1 of the Phase II study, and we look forward to advancing the Part 2 study to determine the optimal dosage of OQL011 for Phase III.”

The trial’s key objectives include the assessment of the efficacy and safety of OQL011 and the identification of an optimal dosage for Phase III.

Exploring the pharmacokinetics profile of OQL011 in HSFR patients is also one of the objectives.

OQL011 acts on the key pathway of VEGFR inhibitor-associated HFSR.

HFSR is a common side effect of tyrosine kinase inhibitors, including VEGFR inhibitors that are used for the treatment of cancer.